Delving into the Latest Updates on Sultan Qaboos University Hospital with Synapse

Overview

Tags

Congenital Disorders

Eye Diseases

Fab fragment

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Fab fragment	1
Biosimilar	1

Top 5 Target	Count

VEGF-A(Vascular endothelial growth factor A)	1

BackgroundOsteoarthritis (OA) is a prevalent disabling joint disease affecting more than 300 million people globally and knees are most commonly affected. It is associated with pain and functional limitation that adversely affect mental well-being and compromise quality of life. Analgesic use is common among patients with knee osteoarthritis (KOA), however, data on patterns of analgesics use at an individual patient level are sparse. The present study describes patterns of analgesic use, by determining the proportion of persistent users within one year of therapy initiation in patients with KOA.MethodsA retrospective cohort study using the clinical practice research datalink. Analgesic prescriptions for adults with an incident KOA diagnosis were captured and grouped into five exposure groups including: antidepressants, antiepileptic drugs (AEDs), opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. A persistent user was a person who used >180 defined daily doses (DDDs) per year and had prescriptions in at least three out of the four quarters of the year.ResultsVariable proportions of patients used respective analgesic classes persistently during the first year after prescribing; 36.8% of antidepressant users, 27.0% of NSAIDs, 23.8% of AEDs, 17.5% of paracetamol and 14.9% of opioid users were persistent users. Across classes, persistent users were slightly younger, were issued more prescriptions and used higher doses of analgesics compared to non-persistent users.ConclusionBetween 14.9% and 36.8% became persistent analgesic users by the end of the first year after their initial prescription. The study applied meaningful clinical attributes to define persistence. This informs future research on clinical and adverse drug outcomes in persistent users compared to non-persistent users across five separate analgesic classes.

01 Jul 2025·Travel Medicine and Infectious Disease

Leishmaniasis in Syria – A call for action of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Travellers and Migrants (ESGITM) and for Clinical Parasitology (ESGCP)

Author: Rizk, Nesrine ; AlKharrat, Ayla ; Morante-Ruiz, Miguel ; Jordão, Sofia ; Rathish, Balram ; Khalife, Mohamad ; Abbara, Salam ; Lakatos, Botond ; Guimarães, André R ; Salvati, Annabella ; Garg, Puja ; Ahmed, Shamsa Hussein ; Alhazmi, Abdulaziz ; González-Sanz, Marta ; Paggi, Riccardo ; Cascio, Antonio ; Alvarez-Martinez, Miriam J ; Di Carlo, Paola ; Ursini, Tamara ; Llenas-García, Jara ; Nwofe, Justin Onyebuchi ; Rath, Barbara ; Farkas, Ferenc Balázs ; Chiodini, Peter ; Nedu, Elena ; Holmberg, Ville ; Barboza, Ana Paula ; Rodriguez-Morales, Alfonso J ; Monk, Edward J M ; Elkheir, Natalie ; Leblebicioglu, Hakan ; Elferruh, Yasir ; Asaduzzaman, Muhammad ; Ronnberg, Caroline ; Priyadarshi, Megha ; Díaz-Menéndez, Marta ; Wejse, Christian Morberg ; Brekke, Hanne ; Kim, Jung-Ah ; Colpani, Agnese ; Losada-Galván, Irene ; Tamarozzi, Francesca ; Marroush, Sana ; Shortall, Clare ; Al Balushi, Asma ; Sempere-Alcocer, Marco Antonio ; Pinho, Jose Henrique ; Ioannou, Petros ; Rezzonico, Leonardo Francesco ; Grüner, Beate ; Costescu Strachinaru, Diana Isabela ; Scarso, Salvatore ; Almhawish, Naser ; Pontali, Emanuele ; Martinez, Gabriela Equihua ; Abbara, Aula ; O'Regan, Rhea ; Tavares, Raquel ; Sepulcri, Chiara ; Verweij, Jaco J

01 May 2025·Clinical Imaging

Exploring the quadrilateral space: Clinical anatomy, pathology, and imaging insights

Review

Author: Pellakuru, S R ; Iyengar, K P ; Mishra, N ; Shah, A ; Shirodkar, K ; Raniga, S ; Saran, S ; Shah, A B ; Botchu, R

Quadrilateral Space Syndrome (QSS) is a rare clinical entity characterised by neurovascular compression within the quadrilateral space, a confined anatomical region bounded by the teres minor, teres major, long head of the triceps brachii, and the surgical neck of the humerus. The syndrome primarily affects the axillary nerve and posterior circumflex humeral artery (PCHA), presenting with nonspecific symptoms such as shoulder pain, paresthesia, and muscle weakness. Imaging plays a pivotal role in diagnosing QSS, with magnetic resonance imaging (MRI) serving as the gold standard. Ultrasound complements MRI by dynamically assessing neurovascular structures and detecting vascular compromise using Doppler imaging. Other imaging modalities, including radiography and computed tomography (CT), are valuable for identifying bony abnormalities or associated space-occupying lesions like osteochondromas or bone tumours. Management of QSS involves a stepwise approach. Conservative treatments, such as physical therapy and ultrasound-guided steroid injections, are first-line interventions aimed at alleviating symptoms and addressing contributing factors. Surgical decompression is reserved for refractory cases, particularly when fibrous bands, space-occupying lesions, or vascular complications such as thrombosis or aneurysms are identified. A thorough understanding of the anatomical and radiological features of QSS, combined with a tailored management strategy, is crucial for optimising outcomes in affected patients. This review aims to provide a comprehensive overview of the clinical anatomy, imaging findings, and management strategies for QSS.

100 Deals associated with Sultan Qaboos University Hospital

Login to view more data

100 Translational Medicine associated with Sultan Qaboos University Hospital

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data